MentalHealthDaily

LY-2456302 For Depression: Kappa Opioid Receptor (KOR) Antagonist

by GLOOM

In recent years, biotech and pharmaceutical companies have been developing new classes of antidepressants. These new classes attempt to improve on older classes of medication in regards to efficacy, side effects, and tolerability. One such class that is being developed is that which targets opioid receptors, particularly the kappa receptor. These drugs are classified as …

2 New Kappa Opioid Receptor (KOR) Antagonists For Depression

by GLOOM

The quest to come up with a superior antidepressant is in full effect among biotech and pharmaceutical companies. Although there are some companies that are still tweaking various formulations of serotonergic, noradrenergic, and dopaminergic substances (e.g. triple reuptake inhibitors) others are thinking outside the box. Based on current trends, the next decade or two of …